Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Abnormal (Dysfunctional) Uterine Bleeding Workup

  • Author: Millie A Behera, MD; Chief Editor: Richard Scott Lucidi, MD, FACOG  more...
 
Updated: Nov 15, 2015
 

Laboratory Studies

Laboratory studies for patients with abnormal uterine bleeding (AUB) include human chorionic gonadotropin (HCG), complete blood count (CBC), Pap smear, endometrial sampling, thyroid functions and prolactin, liver functions, coagulation studies/factors, and other hormone assays as indicated.[5]

Human chorionic gonadotropin

The most common cause of abnormal uterine bleeding during the reproductive years is abnormal pregnancy. Rule out threatened abortion, incomplete abortion, and ectopic pregnancy.

Complete blood count

Document blood loss. Charting the number of menstrual pads used per day, or keeping a menstrual calendar is helpful.

When in doubt, obtain a baseline CBC count for hemoglobin and hematocrit. Rule out anemia. Obtain a differential with platelet count if hematologic disease is suspected.

Pap smear

Pap smear should be up to date. Cervical cancer still is the most common gynecologic cancer affecting women of reproductive age in the world population.

Endometrial sampling

Perform a biopsy to rule out endometrial hyperplasia or cancer in high-risk women >35 years and in younger women at extreme risk for endometrial hyperplasia/carcinoma. Women with chronic eugonadal anovulation, obesity, hirsutism, diabetes, or chronic hypertension are at particular risk.

Most biopsies will confirm the absence of secretory endometrium.

Thyroid and liver function tests

Perform thyroid function tests and prolactin because hyperthyroidism, hypothyroidism, and hyperprolactinemia are associated with ovulatory dysfunction. Identify and treat these conditions.

Obtain liver function tests if alcoholism or hepatitis is suspected. Any condition affecting liver metabolism of estrogen can be associated with abnormal uterine bleeding.

Coagulation factors

Von Willebrand disease and factor XI deficiency initially might manifest during adolescence.

Primary or secondary thrombocytopenia can be factors in the mature patient.

Tailor the choice of laboratory tests to the presenting clinical situation. Generally speaking, when coagulopathies are present, heavy bleeding is regular (menorrhagia) and associated with ovulation.

Other hormone assays

For the patient with recurrent anovulatory bleeding, the mainstay of management is treatment of correctable disease.

Obtain a hormonal complete evaluation in women with signs of hyperandrogenism, such as those with polycystic ovarian syndrome, 21 hydroxylase deficiency, or ovarian or adrenal tumors, as dictated by their respective conditions.

Women in menopausal transition usually can be followed without an extensive hormonal evaluation.

Next

Imaging Studies

Generally, patients with abnormal uterine bleeding can be managed appropriately without the use of expensive imaging studies.

In obese patients with suboptimal pelvic examination or in patients with suspected ovarian or uterine pathology, pelvic ultrasonographic evaluation might be helpful.

Ultrasonography can be used to examine the status of the endometrium. Endometrial hyperplasia, endometrial carcinoma, endometrial polyps, and uterine fibroids can be identified easily by this technology.

Previous
Next

Procedures

Rule out endometrial carcinoma in all patients at high risk for the condition, including patients with the following characteristics:

  • Morbid obesity
  • Diabetes or chronic hypertension
  • Age >35 years
  • Longstanding, chronic eugonadal anovulation

Traditionally, carcinoma was ruled out by endometrial sampling via dilation and curettage (D&C). More recently, endometrial sampling in the office via aspiration, curetting, or hysteroscopy has become popular and is also relatively accurate.

Real-time ultrasonographic measurement and evaluation of the endometrial stripe can be helpful in distinguishing individuals bleeding with thick endometrium from those with thin, denuded endometrium, endometrial polyps, uterine fibroids, or other uterine pathology.

Saline-infusion sonohysterography is also very useful in evaluating for intracavitary (submucosal) fibroids and endometrial polyps.

Most endometrial biopsy specimens will show proliferative or dyssynchronous endometrium.

Previous
 
 
Contributor Information and Disclosures
Author

Millie A Behera, MD Assistant Professor (Adjunct), Division of Reproductive Endocrinology and Fertility, Department of Obstetrics and Gynecology, Duke University Medical Center; Medical Director, Bloom Reproductive Institute

Millie A Behera, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists, American Society for Reproductive Medicine, AAGL

Disclosure: Nothing to disclose.

Coauthor(s)

Thomas Michael Price, MD Associate Professor, Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Director of Reproductive Endocrinology and Infertility Fellowship Program, Duke University Medical Center

Thomas Michael Price, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Obstetricians and Gynecologists, Phi Beta Kappa, Society for Reproductive Investigation, Society for Reproductive Endocrinology and Infertility, American Society for Reproductive Medicine

Disclosure: Received research grant from: Insigtec Inc<br/>Received consulting fee from Clinical Advisors Group for consulting; Received consulting fee from MEDA Corp Consulting for consulting; Received consulting fee from Gerson Lehrman Group Advisor for consulting; Received honoraria from ABOG for board membership.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Frances E Casey, MD, MPH Director of Family Planning Services, Department of Obstetrics and Gynecology, VCU Medical Center

Frances E Casey, MD, MPH is a member of the following medical societies: American College of Obstetricians and Gynecologists, Association of Reproductive Health Professionals, Society of Family Planning, National Abortion Federation, Physicians for Reproductive Health

Disclosure: Nothing to disclose.

Chief Editor

Richard Scott Lucidi, MD, FACOG Associate Professor of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Virginia Commonwealth University School of Medicine

Richard Scott Lucidi, MD, FACOG is a member of the following medical societies: American College of Obstetricians and Gynecologists, American Society for Reproductive Medicine

Disclosure: Nothing to disclose.

Additional Contributors

Anthony Charles Sciscione, DO Professor, Department of Obstetrics and Gynecology, Drexel University College of Medicine; Director, Maternal and Fetal Medicine, Christiana Care Health System; Director, Delaware Center for Maternal and Fetal Medicine

Anthony Charles Sciscione, DO is a member of the following medical societies: American College of Obstetricians and Gynecologists, American Medical Association

Disclosure: Nothing to disclose.

Acknowledgements

The authors and editors of Medscape Drugs & Diseases gratefully acknowledge the contributions of previous author John T Queenan, Jr, MD, to the development and writing of this article.

References
  1. Khrouf M, Terras K. Diagnosis and management of formerly called "dysfunctional uterine bleeding" according to PALM-COEIN FIGO classification and the new guidelines. J Obstet Gynaecol India. 2014 Dec. 64 (6):388-93. [Medline].

  2. [Guideline] James AH, Kouides PA, Abdul-Kadir R, et al. Von Willebrand disease and other bleeding disorders in women: consensus on diagnosis and management from an international expert panel. Am J Obstet Gynecol. 2009 Jul. 201(1):12.e1-8. [Medline].

  3. Bennett AR, Gray SH. What to do when she's bleeding through: the recognition, evaluation, and management of abnormal uterine bleeding in adolescents. Curr Opin Pediatr. 2014 Aug. 26 (4):413-9. [Medline].

  4. Rezk M, Masood A, Dawood R. Perimenopausal bleeding: Patterns, pathology, response to progestins and clinical outcome. J Obstet Gynaecol. 2015 Jul. 35 (5):517-21. [Medline].

  5. Deligeoroglou EK, Creatsas GK. Dysfunctional uterine bleeding as an early sign of polycystic ovary syndrome during adolescence. Minerva Ginecol. 2015 Aug. 67 (4):375-81. [Medline].

  6. Roach L. Uterine Bleeding: ACOG Updates Guidelines. Medscape Medical News. Jun 21 2013. Available at http://www.medscape.com/viewarticle/806735. Accessed: July 10, 2013.

  7. Committee on Practice Bulletins—Gynecology. Practice bulletin no. 136: management of abnormal uterine bleeding associated with ovulatory dysfunction. Obstet Gynecol. 2013 Jul. 122 (1):176-85. [Medline].

  8. Hickey M, Higham JM, Fraser I. Progestogens with or without oestrogen for irregular uterine bleeding associated with anovulation. Cochrane Database Syst Rev. 2012 Sep 12. 9:CD001895. [Medline].

  9. Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ. 2011 Apr 21. 342:d2151. [Medline]. [Full Text].

  10. Teichmann A, Apter D, Emerich J, Greven K, Klasa-Mazurkiewicz D, Melis GB, et al. Continuous, daily levonorgestrel/ethinyl estradiol vs. 21-day, cyclic levonorgestrel/ethinyl estradiol: efficacy, safety and bleeding in a randomized, open-label trial. Contraception. 2009 Dec. 80(6):504-11. [Medline].

  11. Hokenstad AN, El-Nashar SA, Khan Z, Hopkins MR, Famuyide AO. Endometrial ablation in women with abnormal uterine bleeding related to ovulatory dysfunction: a cohort study. J Minim Invasive Gynecol. 2015 Nov-Dec. 22 (7):1225-30. [Medline].

  12. Vitagliano A, Bertin M, Conte L, et al. Thermal balloon ablation versus transcervical endometrial resection: evaluation of postoperative pelvic pain in women treated for dysfunctional uterine bleeding. Clin Exp Obstet Gynecol. 2014. 41(4):405-8. [Medline].

  13. Athanatos D, Pados G, Venetis CA, et al. Novasure impedance control system versus microwave endometrial ablation for the treatment of dysfunctional uterine bleeding: a double-blind, randomized controlled trial. Clin Exp Obstet Gynecol. 2015. 42 (3):347-51. [Medline].

  14. Ash SJ, Farrell SA, Flowerdew G. Endometrial biopsy in DUB. J Reprod Med. 1996 Dec. 41(12):892-6. [Medline].

  15. Bayer SR, DeCherney AH. Clinical manifestations and treatment of dysfunctional uterine bleeding. JAMA. 1993 Apr 14. 269(14):1823-8. [Medline].

  16. Bongers MY, Bourdrez P, Heintz AP, et al. Bipolar radio frequency endometrial ablation compared with balloon endometrial ablation in dysfunctional uterine bleeding: impact on patients' health-related quality of life. Fertil Steril. 2005 Mar. 83(3):724-34. [Medline].

  17. Bongers MY, Mol BW, Brolmann HA. Current treatment of dysfunctional uterine bleeding. Maturitas. 2004 Mar 15. 47(3):159-74. [Medline].

  18. Bourdrez P, Bongers MY, Mol BW. Treatment of dysfunctional uterine bleeding: patient preferences for endometrial ablation, a levonorgestrel-releasing intrauterine device, or hysterectomy. Fertil Steril. 2004 Jul. 82(1):160-6, quiz 265. [Medline].

  19. Casablanca Y. Management of dysfunctional uterine bleeding. Obstet Gynecol Clin North Am. 2008 Jun. 35(2):219-34. [Medline].

  20. Chullapram T, Song JY, Fraser IS. Medium-term follow-up of women with menorrhagia treated by rollerball endometrial ablation. Obstet Gynecol. 1996 Jul. 88(1):71-6. [Medline].

  21. Claessens EA, Cowell CA. Dysfunctional uterine bleeding in the adolescent. Pediatr Clin North Am. 1981 May. 28(2):369-78. [Medline].

  22. Crosignani PG, Rubin B. Dysfunctional uterine bleeding. Hum Reprod. 1990 Jul. 5(5):- Rubin B. [Medline].

  23. Demers C, Derzko C, David M, et al. Gynaecological and obstetric management of women with inherited bleeding disorders. Int J Gynaecol Obstet. 2006 Oct. 95(1):75-87. [Medline].

  24. DeVore GR, Owens O, Kase N. Use of intravenous Premarin in the treatment of dysfunctional uterine bleeding--a double-blind randomized control study. Obstet Gynecol. 1982 Mar. 59(3):285-91. [Medline].

  25. Dodson MG. Use of transvaginal ultrasound in diagnosing the etiology of menometrorrhagia. J Reprod Med. 1994 May. 39(5):362-72. [Medline].

  26. Díaz S, Croxatto HB, Pavez M, et al. Clinical assessment of treatments for prolonged bleeding in users of Norplant implants. Contraception. 1990 Jul. 42(1):97-109. [Medline].

  27. Edlund M, Blomback M, von Schoultz B, et al. On the value of menorrhagia as a predictor for coagulation disorders. Am J Hematol. 1996 Dec. 53(4):234-8. [Medline].

  28. Ely JW, Kennedy CM, Clark EC, et al. Abnormal uterine bleeding: a management algorithm. J Am Board Fam Med. 2006 Nov-Dec. 19(6):590-602. [Medline]. [Full Text].

  29. Falcone T, Desjardins C, Bourque J, et al. Dysfunctional uterine bleeding in adolescents. J Reprod Med. 1994 Oct. 39(10):761-4. [Medline].

  30. Ferenczy A, Gelfand M. The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia. Am J Obstet Gynecol. 1989 Jan. 160(1):126-31. [Medline].

  31. Ferenczy A, Gelfand MM, Tzipris F. The cytodynamics of endometrial hyperplasia and carcinoma. A review. Ann Pathol. 1983 Sep. 3(3):189-201. [Medline].

  32. Franks S, Adams J, Mason H, et al. Ovulatory disorders in women with polycystic ovary syndrome. Clin Obstet Gynaecol. 1985 Sep. 12(3):605-32. [Medline].

  33. Gervaise A, de Tayrac R, Fernandez H. Contraceptive information after endometrial ablation. Fertil Steril. 2005 Dec. 84(6):1746-7. [Medline].

  34. Hopkins MP, Androff L, Benninghoff AS. Ginseng face cream and unexplained vaginal bleeding. Am J Obstet Gynecol. 1988 Nov. 159(5):1121-2. [Medline].

  35. Jayasinghe Y, Moore P, Donath S, et al. Bleeding disorders in teenagers presenting with menorrhagia. Aust N Z J Obstet Gynaecol. 2005 Oct. 45(5):439-43. [Medline].

  36. Kadir RA, Economides DL, Sabin CA, et al. Frequency of inherited bleeding disorders in women with menorrhagia. Lancet. 1998 Feb 14. 351(9101):485-9. [Medline].

  37. LaCour DE, Long DN, Perlman SE. Dysfunctional uterine bleeding in adolescent females associated with endocrine causes and medical conditions. J Pediatr Adolesc Gynecol. 2010 Apr. 23(2):62-70. [Medline].

  38. Lethaby A, Augood C, Duckitt K, et al. Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev. 2007 Oct 17. CD000400. [Medline].

  39. Lethaby A, Farquhar C, Cooke I. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev. 2000. CD000249. [Medline].

  40. Lethaby A, Irvine G, Cameron I. Cyclical progestogens for heavy menstrual bleeding. Cochrane Database Syst Rev. 2008 Jan 23. CD001016. [Medline].

  41. Lethaby AE, Cooke I, Rees M. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev. 2005 Oct 19. CD002126. [Medline].

  42. March CM. Hysteroscopy. J Reprod Med. 1992 Apr. 37(4):293-311; discussion 311-2. [Medline].

  43. Margolis MT, Thoen LD, Boike GM, et al. Asymptomatic endometrial carcinoma after endometrial ablation. Int J Gynaecol Obstet. 1995 Dec. 51(3):255-8. [Medline].

  44. Meyer WR, Walsh BW, Grainger DA, et al. Thermal balloon and rollerball ablation to treat menorrhagia: a multicenter comparison. Obstet Gynecol. 1998 Jul. 92(1):98-103. [Medline].

  45. Munro MG. Dysfunctional uterine bleeding: advances in diagnosis and treatment. Curr Opin Obstet Gynecol. 2001 Oct. 13(5):475-89. [Medline].

  46. Ravn SH, Rosenberg J, Bostofte E. Postmenopausal hormone replacement therapy--clinical implications. Eur J Obstet Gynecol Reprod Biol. 1994 Feb. 53(2):81-93. [Medline].

  47. Rodeghiero F. Management of menorrhagia in women with inherited bleeding disorders: general principles and use of desmopressin. Haemophilia. 2008 Jan. 14 Suppl 1:21-30. [Medline].

  48. Rogers PA, Martinez F, Girling JE, et al. Influence of different hormonal regimens on endometrial microvascular density and VEGF expression in women suffering from breakthrough bleeding. Hum Reprod. 2005 Dec. 20(12):3341-7. [Medline].

  49. Rose EH, Aledort LM. Nasal spray desmopressin (DDAVP) for mild hemophilia A and von Willebrand disease. Ann Intern Med. 1991 Apr 1. 114(7):563-8. [Medline].

  50. Sagiv R, Ben-Shem E, Condrea A, et al. Endometrial carcinoma after endometrial resection for dysfunctional uterine bleeding. Obstet Gynecol. 2005 Nov. 106(5 Pt 2):1174-6. [Medline].

  51. Schneider LG. Causes of abnormal vaginal bleeding in a Family Practice Center. J Fam Pract. 1983 Feb. 16(2):281-3. [Medline].

  52. Smith CB. Dysfunctional uterine bleeding. Am Fam Physician. 1987 Sep. 36(3):161-8. [Medline].

  53. Solnik JM, Guido RS, Sanfilippo JS, et al. The impact of endometrial ablation technique at a large university women's hospital. Am J Obstet Gynecol. 2005 Jul. 193(1):98-102. [Medline].

  54. Speroff L, Glass R, Kase N. Dysfunctional uterine bleeding. Clinical Gynecologic Endocrinology & Infertility. 1999. 575-591.

  55. Strickland JL. Management of abnormal bleeding in adolescents. Mo Med. 2004 Jan-Feb. 101(1):38-41. [Medline].

  56. van Bogaert LJ. Diagnostic aid of endometrium biopsy. Gynecol Obstet Invest. 1979. 10(6):289-97. [Medline].

  57. Van Zon-Rabelink IA, Vleugels MP, Merkus HM, et al. Efficacy and satisfaction rate comparing endometrial ablation by rollerball electrocoagulation to uterine balloon thermal ablation in a randomised controlled trial. Eur J Obstet Gynecol Reprod Biol. 2004 May 10. 114(1):97-103. [Medline].

  58. Wathen PI, Henderson MC, Witz CA. Abnormal uterine bleeding. Med Clin North Am. 1995 Mar. 79(2):329-44. [Medline].

  59. Wilansky DL, Greisman B. Early hypothyroidism in patients with menorrhagia. Am J Obstet Gynecol. 1989 Mar. 160(3):673-7. [Medline].

  60. Wren BG. Dysfunctional uterine bleeding. Aust Fam Physician. 1998 May. 27(5):371-7. [Medline].

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.